21:33 , May 11, 2018 |  BioCentury  |  Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline....
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Qaam Pharmaceuticals, Axovant Sciences deal

Qaam granted Axovant an exclusive license to IP that covers the combination of cholinesterase inhibitors with peripheral muscarinic receptor antagonists. Axovant said the combination could mitigate the peripheral side effects of cholinesterase inhibitors, which are...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

Acino sales and marketing update

Acino launched a generic version of Exelon Patch rivastigmine from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in the U.S. Exelon Patch, an acetylcholinesterase (AChE) inhibitor, is approved in the U.S. to treat mild to moderate...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

Rivastach Patch rivastigmine regulatory update

Ono submitted an application in Japan to amend the label of Rivastach Patch rivastigmine to treat mild to moderate Alzheimer's disease to include an additional dosing regimen in which the initial dose of 9 mg...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Novartis A pharmaceuticals news

Novartis said that an ongoing, internal review of adverse event reporting practices in the pharma’s Japanese Novartis Pharma K.K. (NPKK) business unit has revealed about 10,000 previously unreported individual case safety reports. The pharma said...
07:00 , Sep 16, 2013 |  BioCentury  |  Emerging Company Profile

Cardeus: Microglia blockade

Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc. 's COX-1 inhibitor tamps down neuroinflammation in the brain and could be synergistic with other treatments to keep dementia associated with diseases like Parkinson's in check. Activation of...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Exelon Patch rivastigmine regulatory update

FDA approved an sNDA from Novartis to expand the label of Exelon Patch rivastigmine transdermal patch to include treatment of severe Alzheimer's disease with the 13.3 mg/24 hour dose. The acetylcholinesterase (AChE) inhibitor is approved...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Exelon Patch rivastigmine regulatory update

Novartis disclosed in its 1Q13 earnings that EMA approved an expansion of the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to moderately severe Alzheimer's disease...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Exelon rivastigmine regulatory update

Novartis said in its 4Q12 earnings that EMA's CHMP issued a positive opinion recommending expansion of the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Exelon Patch rivastigmine regulatory update

FDA approved an sNDA to expand the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to moderate dementia associated with Parkinson's disease (PD) and mild to...